Home  |  Contact

Cellosaurus HepaRG (CVCL_9720)

[Text version]

Cell line name HepaRG
Synonyms Hepa-RG
Accession CVCL_9720
Resource Identification Initiative To cite this cell line use: HepaRG (RRID:CVCL_9720)
Comments Group: Patented cell line.
Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-2652.
Characteristics: Can be induced to differentiate into hepatocyte-like cells by exposure to DMSO.
Characteristics: Cell line main applications are sugar and lipid metabolism, physiopathology; drug metabolism and toxicology and viral infection.
Omics: Deep exome analysis.
Omics: Deep proteome analysis.
Omics: Membrane proteome analysis.
Omics: miRNA expression profiling.
Omics: Protein expression by reverse-phase protein arrays.
Omics: Secretome proteome analysis.
Omics: Transcriptome analysis.
Anecdotal: The 'RG' in the cell name stands for Rumin and Gripon, the two scientists that were influential in the establishment of this cell line.
Miscellaneous: This cell line is exclusively produced and controlled by Biopredic International and owned by Inserm. BioPredic sells undifferentiated cell line (HPR101) that can be expanded, passaged, and frozen in-house to prepare a cell bank and differentiated ready-to-use cells (HPR116) that can be used immediately or in a few days after thawing, as a single-use disposable product.
Derived from sampling site: Liver.
Disease Hepatitis C infection (NCIt: C3098)
Hepatocellular carcinoma (NCIt: C3099)
Hepatocellular carcinoma (ORDO: Orphanet_88673)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_FA14 (Hepa-SC )CVCL_B6A6 (HepaRG 5F )CVCL_JJ68 (HepaRG CYP3A4G/7R clone 3 )
CVCL_XI49 (HepaRG-CAR )CVCL_JY39 (HepaRG-hNTCP )CVCL_C0QZ (HepaRG(VC) )
CVCL_WL73 (HPR116 )
Sex of cell Female
Age at sampling Age unspecified
Category Cancer cell line
Web pages http://www.heparg.com/
https://lccl.zucmanlab.com/hcc/cellLines/HepaRG
http://triangleresearchlabs.net/products-hepatocytes/nospin-heparg/
https://www.thermofisher.com/order/catalog/product/HPRGC10
Publications

PubMed=12432097; DOI=10.1073/pnas.232137699
Gripon P., Rumin S., Urban S., Le Seyec J., Glaise D., Cannie I., Guyomard C., Lucas J., Trepo C., Guguen-Guillouzo C.
Infection of a human hepatoma cell line by hepatitis B virus.
Proc. Natl. Acad. Sci. U.S.A. 99:15655-15660(2002)

PubMed=17241619; DOI=10.1016/j.cbi.2006.12.003
Guillouzo A., Corlu A., Aninat C., Glaise D., Morel F., Guguen-Guillouzo C.
The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics.
Chem. Biol. Interact. 168:66-73(2007)

PubMed=17393521; DOI=10.1002/hep.21536
Cerec V., Glaise D., Garnier D., Morosan S., Turlin B., Drenou B., Gripon P., Kremsdorf D., Guguen-Guillouzo C., Corlu A.
Transdifferentiation of hepatocyte-like cells from the human hepatoma HepaRG cell line through bipotent progenitor.
Hepatology 45:957-967(2007)

Patent=US7456018
Gripon P., Guguen-Guillouzo C., Trepo C., Rumin S.
Human hepatoma lines, methods for obtaining same and uses thereof.
Patent number US7456018, 25-Nov-2008

PubMed=20228232; DOI=10.1124/dmd.109.031831
Hart S.N., Li Y., Nakamoto K., Subileau E.-A., Steen D., Zhong X.-B.
A comparison of whole genome gene expression profiles of HepaRG cells and HepG2 cells to primary human hepatocytes and human liver tissues.
Drug Metab. Dispos. 38:988-994(2010)

PubMed=20645056; DOI=10.1007/978-1-60761-688-7_13
Marion M.-J., Hantz O., Durantel D.
The HepaRG cell line: biological properties and relevance as a tool for cell biology, drug metabolism, and virology studies.
Methods Mol. Biol. 640:261-272(2010)

PubMed=21414303; DOI=10.1016/j.bcp.2011.03.004
Ceelen L., De Spiegelaere W., David M., De Craene J., Vinken M., Vanhaecke T., Rogiers V.
Critical selection of reliable reference genes for gene expression study in the HepaRG cell line.
Biochem. Pharmacol. 81:1255-1261(2011)

PubMed=22568886; DOI=10.1517/17425255.2012.685159
Andersson T.B., Kanebratt K.P., Kenna J.G.
The HepaRG cell line: a unique in vitro tool for understanding drug metabolism and toxicology in human.
Expert Opin. Drug Metab. Toxicol. 8:909-920(2012)

PubMed=22594799; DOI=10.3109/13813455.2012.683442
Samanez C.H., Caron S., Briand O., Dehondt H., Duplan I., Kuipers F., Hennuyer N., Clavey V., Staels B.
The human hepatocyte cell lines IHH and HepaRG: models to study glucose, lipid and lipoprotein metabolism.
Arch. Physiol. Biochem. 118:102-111(2012)

PubMed=22643240; DOI=10.1016/j.tiv.2012.05.008
Antherieu S., Chesne C., Li R.-Y., Guguen-Guillouzo C., Guillouzo A.
Optimization of the HepaRG cell model for drug metabolism and toxicity studies.
Toxicol. In Vitro 26:1278-1285(2012)

PubMed=22857383; DOI=10.1186/1477-5956-10-47
Sokolowska I., Dorobantu C., Woods A.G., Macovei A., Branza-Nichita N., Darie C.C.
Proteomic analysis of plasma membranes isolated from undifferentiated and differentiated HepaRG cells.
Proteome Sci. 10:47.1-47.13(2012)

PubMed=23887712; DOI=10.1038/ncomms3218
Nault J.-C., Mallet M., Pilati C., Calderaro J., Bioulac-Sage P., Laurent C., Laurent A., Cherqui D., Balabaud C., Zucman-Rossi J.
High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions.
Nat. Commun. 4:2218.1-2218.7(2013)

PubMed=26160117; DOI=10.1093/toxsci/kfv136
Sison-Young R.L.C., Mitsa D., Jenkins R.E., Mottram D., Alexandre E., Richert L., Aerts H., Weaver R.J., Jones R.P., Johann E., Hewitt P.G., Ingelman-Sundberg M., Goldring C.E.P., Kitteringham N.R., Park B.K.
Comparative proteomic characterization of 4 human liver-derived single cell culture models reveals significant variation in the capacity for drug disposition, bioactivation, and detoxication.
Toxicol. Sci. 147:412-424(2015)

PubMed=26694163; DOI=10.1371/journal.pone.0144924
Janiszewska J., Szaumkessel M., Kostrzewska-Poczekaj M., Bednarek K., Paczkowska J., Jackowska J., Grenman R., Szyfter K., Wierzbicka M., Giefing M., Jarmuz-Szymczak M.
Global miRNA expression profiling identifies miR-1290 as novel potential oncomiR in laryngeal carcinoma.
PLoS ONE 10:E0144924-E0144924(2015)

PubMed=27027780; DOI=10.1007/s10565-016-9316-2
Wu Y., Geng X.-C., Wang J.-F., Miao Y.-F., Lu Y.-L., Li B.
The HepaRG cell line, a superior in vitro model to L-02, HepG2 and hiHeps cell lines for assessing drug-induced liver injury.
Cell Biol. Toxicol. 32:37-59(2016)

PubMed=27169750; DOI=10.1038/srep24709
Sharanek A., Burban A., Burbank M., Le Guevel R., Li R., Guillouzo A., Guguen-Guillouzo C.
Rho-kinase/myosin light chain kinase pathway plays a key role in the impairment of bile canaliculi dynamics induced by cholestatic drugs.
Sci. Rep. 6:24709-24709(2016)

PubMed=27780834; DOI=10.1124/dmd.116.072603
van der Mark V.A., de Waart D.R., Shevchenko V., Oude Elferink R.P.J., Chamuleau R.A.F.M., Hoekstra R.
Stable overexpression of the constitutive androstane receptor reduces the requirement for culture with dimethyl sulfoxide for high drug metabolism in HepaRG cells.
Drug Metab. Dispos. 45:56-67(2017)

PubMed=27975304; DOI=10.1007/978-1-4939-6700-1_2
Ni Y., Urban S.
Hepatitis B virus infection of HepaRG cells, HepaRG-hNTCP cells, and primary human hepatocytes.
Methods Mol. Biol. 1540:15-25(2017)

PubMed=28904299; DOI=10.2131/jts.42.641
Tomida T., Ishimura M., Iwaki M.
A cell-based assay using HepaRG cells for predicting drug-induced phospholipidosis.
J. Toxicol. Sci. 42:641-650(2017)

PubMed=30795634; DOI=10.3390/cells8020192
Tascher G., Burban A., Camus S., Plumel M.I., Chanon S., Le Guevel R., Shevchenko V., Van Dorsselaer A., Lefai E., Guguen-Guillouzo C., Bertile F.
In-depth proteome analysis highlights HepaRG cells as a versatile cell system surrogate for primary human hepatocytes.
Cells 8:192.1-192.25(2019)

PubMed=31063779; DOI=10.1053/j.gastro.2019.05.001
Caruso S., Calatayud A.-L., Pilet J., La Bella T., Rekik S., Imbeaud S., Letouze E., Meunier L., Bayard Q., Rohr-Udilova N., Peneau C., Grasl-Kraupp B., de Koning L., Ouine B., Bioulac-Sage P., Couchy G., Calderaro J., Nault J.-C., Zucman-Rossi J., Rebouissou S.
Analysis of liver cancer cell lines identifies agents with likely efficacy against hepatocellular carcinoma and markers of response.
Gastroenterology 157:760-776(2019)

PubMed=33441761; DOI=10.1038/s41598-020-79952-1
Heintze T., Klein K., Hofmann U., Zanger U.M.
Differential effects on human cytochromes P450 by CRISPR/Cas9-induced genetic knockout of cytochrome P450 reductase and cytochrome b5 in HepaRG cells.
Sci. Rep. 11:1000-1000(2021)

Cross-references
Cell line collections Millipore; C103485 - Discontinued
Anatomy/cell type resources BTO; BTO:0005736
Encyclopedic resources Wikidata; Q54882834
Experimental variables resources EFO; EFO_0001186
Metabolomic databases MetaboLights; MTBLS78
Polymorphism and mutation databases Cosmic; 2162524
Proteomic databases PRIDE; PXD001107
PRIDE; PXD004752
PRIDE; PXD006267
PRIDE; PXD010304
Entry history
Entry creation06-Jun-2012
Last entry update22-Sep-2022
Version number26